BMC infectious diseases · 2025
Daptomycin versus beta-lactam based therapy for the treatment of enterococcal endocarditis and other endovascular infections: a retrospective cohort study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perera Vindya, Wardlow Lynn, Sobhanie Mohammad M, Coe Kelci, Leininger Jessica M
Аннотация
BACKGROUND: Daptomycin has a favorable efficacy and safety profile against enterococcal infections, but it is currently a last line treatment for enterococcal infective endocarditis (EIE) due to limited evidence supporting its use.
METHODS: This study aimed to investigate clinical outcomes among patients with EIE who received daptomycin versus beta-lactam based therapy. This was a single-center, retrospective cohort study of hospitalized patients with documented EIE and definitive treatment with daptomycin or beta-lactam based therapy between 2011 and 2023. The primary outcome was clinical failure (composite of inpatient infection-related mortality and progression of disease leading to change in therapy). Descriptive statistics assessed baseline demographics, clinical data, and outcomes between patients who received daptomycin versus beta-lactams.
RESULTS: Twenty-six patients receiving daptomycin (median 10 mg/kg/dose) were compared to 102 receiving beta-lactam based therapy (81% ampicillin and ceftriaxone). No significant difference in clinical failure was observed between groups (0% daptomycin vs. 6% beta-lactam; p = 0.35). Individual components of the primary outcome, all-cause mortality, and adverse events leading to therapy discontinuation were similar between groups.
CONCLUSIONS: Outcomes were similar among patients with EIE treated with daptomycin versus beta-lactams. Larger, prospective studies are needed to confirm this finding.
METHODS: This study aimed to investigate clinical outcomes among patients with EIE who received daptomycin versus beta-lactam based therapy. This was a single-center, retrospective cohort study of hospitalized patients with documented EIE and definitive treatment with daptomycin or beta-lactam based therapy between 2011 and 2023. The primary outcome was clinical failure (composite of inpatient infection-related mortality and progression of disease leading to change in therapy). Descriptive statistics assessed baseline demographics, clinical data, and outcomes between patients who received daptomycin versus beta-lactams.
RESULTS: Twenty-six patients receiving daptomycin (median 10 mg/kg/dose) were compared to 102 receiving beta-lactam based therapy (81% ampicillin and ceftriaxone). No significant difference in clinical failure was observed between groups (0% daptomycin vs. 6% beta-lactam; p = 0.35). Individual components of the primary outcome, all-cause mortality, and adverse events leading to therapy discontinuation were similar between groups.
CONCLUSIONS: Outcomes were similar among patients with EIE treated with daptomycin versus beta-lactams. Larger, prospective studies are needed to confirm this finding.